Paris, France

Pierre Tiollais

This inventor holds 30 USPTO granted patents, plus 3 CIPO patents, primarily in HIV Research. Top assignees: Institut Pasteur, Centre National De La Recherche Scientifique, Yeda Research and Develpment & Co. Ltd. Active years: 1983-2013.


% Patents Active = 96.7


Average Co-Inventor Count = 3.7

ph-index = 8

Forward Citations = 490(Granted Patents)


Location History:

  • 75013 Paris, FR (1995)
  • Paris, FR (1983 - 2013)

Company Filing History:


Years Active: 1983-2013

Loading Chart...
Loading Chart...
Areas of Expertise:
HIV-1 Detection
Recombinant Adenovirus
Hepatitis B Virus
Nucleotide Sequences
DNA Transformation
Interferon Production
Diagnostic Methods
Vaccine Fabrication
Gene Expression
Synthetic Ligand
Cloned DNA Sequences
Eukaryotic Cells
30 patents (USPTO):Explore Patents

Title: Inventor Pierre Tiollais - Revolutionizing Technology in Paris

Introduction: Pierre Tiollais is a renowned inventor based in Paris, France, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Pierre Tiollais holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovative spirit.

Career Highlights: With a career spanning over two decades, Pierre Tiollais has worked with leading research institutions and technology companies to develop cutting-edge solutions that have had a significant impact on various industries.

Collaborations: Throughout his career, Pierre Tiollais has collaborated with top scientists, engineers, and inventors from around the world, fostering a culture of innovation and knowledge sharing.

Conclusion: Pierre Tiollais continues to push the boundaries of technology and innovation, leaving a lasting legacy in the field of invention. His passion for creating solutions to complex challenges sets him apart as a visionary inventor in Paris, France.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…